Kornimate/medical-research-clean huggingface dataset:
mobile care-app to promote coping for caregivers of patients receiving stem cell transplant

Conditions: Bone Marrow Transplant Complications; Hematologic Malignancy

Summary: the goal of this research study is to determine whether a self-administered, psychosocial mobile application (care app) is effective at improving the quality of life and experience of caregivers of patients receiving hematopoietic stem cell transplantation (hct).

this is a randomized clinical trial to determine whether a psychosocial mobile application (care app) is effective at improving the quality of life and experience of caregivers of patients receiving hematopoietic stem cell transplantation (hct). the care app was developed with the goal of addressing the needs of caregivers of hct recipients. participants will be randomized into one of two study groups: care app plus usual care versus usual care. participation in this study is expected to last up to 100 days after hct. it is expected that about 120 people will take part in this research study. the leukemia and lymphoma society is supporting this research by providing funding.

Eligibility criteria:
caregiver inclusion criteria: * adult caregivers (\>18 years) who is a relative or friend who live with the patient or is a designated caregiver as indicated during the transplant process. * caregiver of a patient receiving allogeneic or autologous hct for the treatment of cancer * ability to comprehend and speak english as the care app is only available in english patient exclusion criteria: * caregivers of patients undergoing hct for benign hematologic conditions * caregivers with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures

Keywords: cognitive behavioral therapy cbt hematopoietic stem cell transplantation hct bone marrow transplant complications hematologic malignancy
the efficacy of nutrilite all-plant protein booster to improve sarcopenia and osteoarthritis in middle-aged and elderly people

Conditions: Osteoarthritis; Sarcopenia

Summary: the goal of this clinical trial is to learn whether amway nutrilite all-plant protein booster prototype product (test product) will improve sarcopenia (sa) and osteoarthritis (oa) in middle-aged and elderly people. it will also learn about the improvement of quality of life (qol) in them. the main questions it aims to answer are: * does the test product will improve the sa in terms of short physical performance battery (sppb score) after 12 weeks' intervention? * does the test product will improve the oa in terms of western ontario and mcmaster universities arthritis (womac index) after 12 weeks' intervention? researchers will compare amway all-plant protein booster prototype product to a placebo (a look-alike substance that contains no similar active nutrient ingredients) to see if the test product works to improve sa and oa. participants will: * take the test product or a placebo 2 spoons (15g) twice per day for 12 weeks * visit the site on the baseline day and the 84th day (end day of 12 weeks) for checkups and tests


Eligibility criteria:
inclusion criteria: * be age 50 to 70 years, female and male * participants will be required to have mild to moderately oa \& sa evaluated by kellgren-lawrence i-iii and sarc-cal, respectively * participants need to be competent i.e., able to understand what is to take place and able to provide a free decision on agreeing to the activity/taking part on the study on this * participants must be able to read and understand study instructions and any other relevant study documents * willing to following the lifestyle restrictions as detailed in the information sheet for study * will to give written informed consent exclusion criteria: * have a fever currently, or for 24 hours before enrollment * currently participating in another clinical study * have taken other protein powder products and dietary supplements or medicines containing peptides or hyaluronic acid within the past 6 months (subject to product instructions) * individuals receiving medical treatment that, in the opinion of the principal investigator or study physician, may interfere with test results * the participant is an employee of amway or sprim medical * subject who is in the treatment of gastrointestinal diseases * subject with abnormal liver function tests (alanine aminotransferase and aspartate aminotransferase), kidney function tests (blood urea nitrogen and creatinine), blood routine, urine routine, fecal occult blood test, or electrocardiogram. * subjects have any of the following medical history or have been clinically examined to have the following diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases

Keywords: amway nutrilite all-plant protein booster sppb womac whoqol bref sf-36 cfq 11 sfq
study of depressive symptoms predicting postoperative cognitive dysfunction

Conditions: Postoperative Cognitive Dysfunction; Postoperative Delirium; Depressive Symptoms

Summary: postoperative cognitive dysfunction (pocd) describes a condition where cognitive functions such as attention, perception, concentration, learning, abstract thinking and problem solving are impaired postoperatively. these changes can be resolved after weeks and months. in some cases, changes are permanent.

the aetiology of pocd is multifactorial. one described risk factor is preoperative existing depressive symptoms in patients undergoing cardiac surgery. a total of 300 consecutive patients and 80 healthy controls will be enrolled in this study. patients will be followed up at 7 days, 3 months and 1 year postoperatively. the co gnitive function will be tested and compared to tests done before surgery. postoperatively - from the day of operation until the 7th day (except day 6) - grade of sedation, agitation, signs of delirium, pain, cardiac, respiratory, renal and infectious complications will be monitored. next to preoperative depressive symptoms we will also evaluate a diagnosed depression, anxiety, pain, health-related quality of life, physical comorbidities, adrenal cortical insufficiency, type of anaesthesia, intraoperative blood loss, organ complications, postoperative delirium, baseline cognitive functioning and the number of operations/anaesthetics in the study period after the initial operation as further potential predictors of pocd. in addition, laboratory values and certain medications will be documented. these include: anaemia, hypercalcaemia, thyroidal gland hormones, electrolytes, creatinine, urea, glomerular filtration rate and cortisone therapy.

Eligibility criteria:
inclusion criteria for patients and healthy controls: * age \> 60 years * written informed patient's consent additional inclusion criteria for patients: * elective non-cardiac surgery and non-neurosurgical procedures in general anaesthesia or combined general/regional anaesthesia * minimum of duration of operation 120 minutes * baseline testing 3-14 days preoperatively additional inclusion criteria for healthy controls: * matched for age, gender and education * no surgery over the study period exclusion criteria for patients and healthy control: * german not mother tongue * illiteracy * mental disability * vision impairment not correctable * hearing impairment not correctable * illegal substance abuse (current or past history) * alcohol abuse (current or past history) * chronic benzodiazepine use * psychosis (current or past history) * parkinson disease * dementia * multiple sclerosis * epilepsy (current or past history) * cerebral tumor (current or past history) * apoplexy or intracranial bleeding (current or past history) * severe traumatic brain injury (current or past history) * severe liver disease (child pugh b, c, liver insufficiency) * severe kidney disease with dialysis * mini mental status examination \< 24 points
effect of breastfeeding optimization on early vascular development

Conditions: Breast Feeding; Cardiovascular Diseases

Summary: this study aims to find out whether breast feeding optimization will increase breast feeding rates and to evaluate its effect on cardiovascular risk and general health of children.

breast feeding is suggested to give many benefits for babies and there are some initial prove that it might affect their future health, including the development of cardiovascular diseases. in indonesia, breast feeding rates are very low, while there is a strong upsurge of cardiovascular disease. in this study, we propose to randomly allocate pregnant indonesian women who plan to give breast feeding for no more than two months, to either care as usual or to a breast feeding empowerment program lasting to 6 months post partum. at the age of one year, all randomized offspring will undergo non-invasive echographic aortic vascular measurements and cardiovascular risk profiling. measurements for assessing children's general health status will also be performed, including growth monitoring, repeated lung function test, and microbiomic sampling.

Eligibility criteria:
inclusion criteria * plan to breast feed for ≤2 months * residing in vicinity ≤ 5 km from the hospital/agree to comply to health visit schedule * telephone communication is possible * no known hiv or active tuberculosis in mother * uncomplicated pregnancy

Keywords: breast feeding cardiovascular risk
intervening on women's health for rural young breast cancer survivors

Conditions: Breast Cancer; Fertility; Contraception; Menopausal Symptoms

Summary: the purpose of this study is to evaluate the effectiveness of a multi-component intervention to improve young breast cancer survivors' engagement in goal-concordant oncofertility care, concurrently with observing and gathering information on how the intervention is implemented. the investigators hypothesize that implementation of the intervention will result in increased young breast cancer survivors' engagement in goal-concordant oncofertility care.


Eligibility criteria:
inclusion criteria: * breast cancer (stages 0-iv) diagnosis * primary language english or spanish * receiving oncology care at participating clinical sites * living in imperial county, california exclusion criteria: - women who are pregnant at recruitment

Keywords: oncofertility
prediction of lupus renal flares study

Conditions: Systemic Lupus Erythematosus

Summary: in patients with systemic lupus erythematosus, urinary cd4+ t cells may have the potential to predict subsequent renal flares in the next 6 months. patients with systemic lupus erythematosus from our outpatient clinic will be included in this cross-sectional, prospective biomarker study regardless of disease activity, clinical phenotype, and disease duration or baseline therapy. urinary t cells will be analyzed by flow cytometry. 6 months after sample collection a clinical follow-up will be conducted to assess the occurrence of either recurrent or de novo renal flares.


Eligibility criteria:
inclusion criteria: * informed consent * diagnosis of sle according to the 2019 eular/acr classification criteria stable immunosuppressive or biologic background therapy within the last 6 months prior to inclusion exclusion criteria: * age \< 18 * inability to consent * urinary tract infection (defined by detection of nitrite or positive urine culture) * patients on chronic dialysis * concomitant other autoimmune disease

Keywords: systemic lupus erythematosus lupus nephritis flow cytometry cd4-positive t-lymphocytes biomarker urine specimen collection
pain control in pediatric oncology: utility of emla cream vs lidocaine injection in lumbar punctures

Conditions: Leukemia-Lymphoma

Summary: a common procedure in children with cancer is the spinal tap, or lumbar puncture (lp), in which a needle is inserted into the spinal canal. in this population, lps are most commonly performed to collect cerebrospinal fluid (csf, the liquid surrounding the brain and spinal cord) for diagnostic testing, and to inject medications including chemotherapy. local analgesic (pain control medicine) during pediatric lp procedures is underutilized and not standardized. the first local analgesic routinely used for lp procedures was lidocaine injection. the discovery of the topical emla (lidocaine 2.5%/prilocaine 2.5%) cream, approved by the fda for local skin use in pediatric patients, has provided an additional option for local lp analgesia. a comparison between topical emla vs lidocaine injection for lp pain control in the pediatric population has not been performed. pediatric oncology patients often require serial lps for diagnostics purposes and/or chemotherapy delivery. due to a lack of standardization of lp analgesia in this population, the investigators have designed a prospective, single-blind, randomized control crossover trial to examine emla vs. lidocaine injection in reducing pain associated with lp in children being treated for leukemia or lymphoma.


Eligibility criteria:
inclusion criteria: * pediatric cancer patients (aged 3-18) with a diagnosis of leukemia or lymphoma * patients are expected to receive serial (i.e. \> 1) lp as outpatients in charleston area medical center children's cancer center in the course of 12 months for diagnostic and/or treatment purposes exclusion criteria: * patients not in the age range * non-cancer patients * allergy to amide anesthetics * patients treated with class i and iii anti-arrhythmic drugs (eg, amiodarone, bretylium, sotalol, dofetilide) * patients with congenital or idiopathic methemoglobinemia
ipad use in reducing anxiety and depression in patients undergoing bone marrow transplant

Conditions: Anxiety; Depression; Malignant Neoplasm

Summary: this randomized clinical trial studies ipad use in reducing anxiety and depression in patients undergoing bone marrow transplant. a tablet device like the ipad can provide access to music, television, movies, books, and the internet. it also contains a video conferencing system that can allow patients to communicate with family members and other members of their social support team. with these capabilities, an ipad distribution program may help lessen patient anxiety and depression during a hospital stay. monitoring ipad use by patients may help doctors better understand how patients use their computers and tablets while in the hospital so that the software and applications of the ipad can be made more useful.

primary objectives: i. to evaluate the effect access to an ipad has on anxiety as measured by the hospital anxiety and depression scale. secondary objectives: i. determine how computers and tablets are used by patients who have access to such devices. outline: participants are assigned to group a or randomized to 1 of 2 groups (groups b or c). group a (participants provide their own computer or tablet device): a member of the research personnel helps the participants install netflix, spotify, and skype applications on their computers if they wish to do so. participants will be given subscriptions to each application and usernames for access on days -5 to 10. group b (apple ipad): participants receive an ipad for days -5 to 10. participants also receive the buckipad manual for instructions on how to use the ipad and netflix, skype, and spotify applications. participants are also directed to the official apple's ipad user's manual on their device and have questions answered by research personnel on day -5. group c: participants do not receive an ipad for days -5 to 10.

Eligibility criteria:
inclusion criteria: * adult patients undergoing treatment in the bone marrow transplant (bmt) unit on the 3rd floor of the james cancer hospital and solove research institute * patients receiving reduced intensity chemotherapy for an allogeneic stem cell transplant exclusion criteria: * patients who lack the visual or motor skills necessary to use a tablet device like the apple ipad * criteria for visual proficiency will be determined by asking the patient: do you have trouble reading a newspaper even with your glasses or contacts (if you wear them); if "yes", they will be excluded * criteria for motor skill proficiency will be determined by asking the patient: do you have any trouble using a television remote control; if "yes", they will be excluded * patients who do not speak english
longitudinal sv2a and mri in premanifest hd

Conditions: Huntington Disease

Summary: aim: to compare the sensitivity of sv2a pet and volumetric mri to detect longitudinal striatal changes in premanifest hd. design: the investigators will include late premanifest hd mutations carriers and matched healthy controls. all subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 18f-synvest-1 pet and volumetric mri at baseline and after 2 years.


Eligibility criteria:
inclusion criteria: * age 20-75 years inclusive. * capacity to understand the informed consent form. * hd mutation carriers: * htt (cag)n ≥ 40 * hd-iss \< 2 * cap100 score \> 70 exclusion criteria: * neuropsychiatric diseases (other than hd for hd mutation carriers) * major internal medical diseases * white matter lesion load on flair fazekas score 2 or higher or other relevant mri abnormalities * history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse * contraindications for mr * pregnancy * previous participation in other research studies involving ionizing radiation with more than 1 msv in the previous 12 months.

Keywords: pet mri sv2a synaptic density 18f-synvest-1
the effect of berries on lung cancer tumors

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to determine how berries affect cancer tumors in patients with non-small cell lung cancer.

in the united states, more people (161,840 per year) die of lung cancers than of prostate cancer, breast cancer and colon cancer combined. presently, there are over 43 million current smokers and over 47 million ex-smokers living in the us. due to the lag time between smoking and the development of cancer, there are significant numbers of ex-smokers and current smokers who may develop lung cancer compared to never smokers. recent studies in animals have shown that berries, given as a dietary supplement, are highly effective against certain types of cancers. in a study involving mice with lung tumors, mice that had consumed a mixture of berries developed fewer tumors and had less tumor growth than mice that did not consume berries. the berries used in this study will consist of blueberries, black raspberries, or a mixture of both.

Eligibility criteria:
inclusion criteria (lung cancer survivors): * men treated for lung cancer, women treated for lung cancer and with no child-bearing potential (hysterectomy, tubal ligation, post-menopausal women) exclusion criteria (lung cancer survivors): * women who are on hormone replacement therapy * women who are pregnant, or planning for pregnancy * history of lung transplant * prison inmate * inability to take oral medication or food * known or suspected allergy to berries or berry products * hiv patients inclusion criteria (volunteers): * adult men, adult women with no child bearing potential (hysterectomy, tubal ligation, post-menopausal women) exclusion criteria (volunteers): * women who are on hormone replacement therapy * women who are pregnant, or planning for pregnancy * history of lung transplant * prison inmate * inability to take oral medication or food * known or suspected allergy to berries or berry products * hiv patients

Keywords: nsclc lung cancer non small cell lung cancer lung carcinoma
evaluate capsular apposition to intraocular lens

Conditions: Capsule Opacification; Tissue Adhesions; Aphakia - Lens Capsule Present; Opacification of Intraocular Lens

Summary: in this study, the investigators examined the capsule-iol interaction including anterior and posterior capsule adhesion, contact between posterior capsule and the posterior edge of intraocular lense (iol), configuration of capsular bend and the incidence of posterior capsular opacity (pco) between high myopia eyes and emmetropia eyes.

150 eyes of 150 cataract patients scheduled for phacoemulsification surgery were recruited, of which 20 eyes were high myopia (al \> 26mm) and 40 eyes were emmetropia (22 \< al \< 25mm) as control group.high myopia eyes and 20 emmetropia eyes were implanted with the single-piece hydrophobic acrylic iol (acrysof iq sn60wf, alcon laboratories, inc. iq group). another 20 emmetropia eyes were implanted with the other single-piece hydrophilic acrylic iol (akreos adapt, bausch \&lomb, ao group).80 eyes implanted with the single-piece hydrophobic acrylic iol were examined by ssoct to build the 3-d model of anterior segment. methods: 60 eyes were examined by custom-built ul-oct at 4 hours, 1 day, 7 day, 14 day, 28 day, 3 month, 6 month,12 month after surgery.30 eyes implanted with the single-piece hydrophobic acrylic iol were recruited for evaluation of the ssoct reliability.50 eyes were examined by ssoct at 1 day, 7 day,1 month, 3 months,6 months,12 months after surgery. measures: contact of the anterior and posterior lens capsule with the iol optic surface was evaluated. types of capsular bend were described at the last follow-up. the incidence of posterior capsular opacity (pco) was evaluated.

Eligibility criteria:
inclusion criteria: * eyes with an al of 26.00mm or more were recruited to the high myopia group. * eyes with an al of 22.00 to 25.00 mm were recruited to the emmetropia group. exclusion criteria: * preoperative exclusion criteria included diabetes, history of ocular surgery or inflammation, pupils could not be dilated over 7mm after mydriasis, * patients who could not be available for follow-up.

Keywords: iol; capsule； pco; oct
impact of intravascular ultrasound guidance on outcomes of xience prime stents in long lesions (ivus-xpl study)

Conditions: Coronary Artery Disease

Summary: this study is designed as a prospective, randomized, multi-center trial to demonstrate an inequality between ivus-guided versus angiography-guided implantation of everolimus-eluting stents(ees) at long lesions(\> 28 mm) in clinical outcomes at 12 months as a primary objective and safety of 6- month dual antiplatelet therapy following ees implantation in comparison with a 12-month dual antiplatelet therapy.

the primary purpose of this study is to investigate the impact of ivus guidance on the clinical outcomes after implantation of des at long lesions \> 28 mm.

Eligibility criteria:
inclusion criteria: * age 20 years old or older * patients with typical chest pain or evidences of myocardial ischemia (e.g., stable, unstable angina, silent ischemia and positive functional study or reversible changes in the electrocardiogram (ecg) consistent with ischemia * non-emergent conditions * patients with signed informed consent * stent length ≥28 mm by angiography estimation * significant coronary artery stenosis (\> 50% by visual estimate) considered for coronary revascularization with stent implantation * reference vessel diameter of 2.5 to 4.0 mm by operator assessment exclusion criteria: * acute st elevation myocardial infarction within 48 hours * contraindication to anti-platelet agents \& bleeding history within prior 3 months * known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, zotarolimus or other -limus group * prior history of the following presentations * cerebral vascular accident (not including transient ischemic attack) * peripheral artery occlusive diseases * thromboembolic disease * stent thrombosis * age \> 80 years old * severe hepatic dysfunction (3 times normal reference values) * significant renal dysfunction (serum creatinine \> 2.0 mg/dl) * significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis * cardiogenic shock * lvef \< 40% * pregnant women or women with potential childbearing * life expectancy \< 1 year * left main disease requiring pci * bifurcation lesion with 2-stent technique * chronic total occlusion * presence of previously implanted des within 6-month * in-stent restenosis lesion